TearSolutions Inc. is a biotechnology company based in Charlottesville, VA, dedicated to developing a transformative therapy for Dry Eye Disease. Their proprietary peptide therapy, LacripepTM, derived from the naturally occurring tear protein Lacritin, has shown promising results in restoring corneal health and reducing symptoms in patients with Dry Eye. With a focus on preserving the bioactivity of Lacritin, TearSolutions aims to provide a natural and effective solution for this under-diagnosed and under-treated eye disease.
Led by a team of experienced ophthalmology professionals, including President and CEO Anil C. Asrani and Chief Scientific Officer Dr. Gordon W. Laurie, TearSolutions is committed to advancing the field of Dry Eye treatment. Their first-in-human Phase I/II trial in primary Sjögren's Syndrome, a severe form of Dry Eye, demonstrated rapid improvement in corneal health and symptom reduction. With millions of people affected by Dry Eye Disease worldwide, TearSolutions' innovative approach offers hope for those seeking relief from this common eye condition.
Generated from the website